Mark Elliott Boulding, Executive VP AND CLO at PTC THERAPEUTICS, INC. (PTCT), sold 2,813 shares at $72.39 ($204K) on 2026-08-17, disclosed to the SEC on 2026-08-19.
Scheduled sale ($204k) by Executive VP AND CLO under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $72.39 | 1,844 | $133K | 65.4% |
| 2 | $72.90 | 969 | $71K | 34.6% |
| Total | $72.57 avg | 2,813 | $204K | 100% |
| Filing → |
| PTCT | SELL | 2026-06-22 | $823K | — | Filing → |
| PTCT | SELL | 2026-05-19 | $203K | — | Filing → |
| PTCT | SELL | 2026-05-12 | $280K | — | Filing → |